Default company panoramic image
Logo

Xdynia

A pharmaceutical company that develops drugs that block Cav3.2 for the prevention & treatment of neuropathic pain.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Charlottesville, VA, USA
  • Currency USD
  • Founded April 2012
  • Employees 8
  • Website xdynia.com

Company Summary

Xdynia is a drug development company that possesses drugs targeting Cav3.2 for the prevention & treatment of neuropathic pain. Chronic pain affects 76 million Americans with 60% reporting no relief from available therapies. Whether caused by diabetes, shingles, fibromyalgia, “slipped disk”, chemotherapy or cancer, the Cav3.2 is a common pathway. A potential $25 B market, Xdynia is poised to introduce a better class of drugs to treat pain.

Team

  • Default avatar
    Yuri Maricich M.D., M.B.A.
    President

    physician & MBA, Harvard, previous founder of health IT firm & research institute. Experienced consultant, physician, & investor.

  • Default avatar
    Andrew Krouse
    Chairman of the Board

    President & CEO of Tau Therapeutics, Former VP of University of Virginia Darden School Foundation. Goldman Sachs, NYC. Three inventions. U. of MD Business School, Master's Georgetown University, the Exec Program at Darden Graduate School of Business

  • Default avatar
    Vesna Todorovic MD PhD
    Pain Researcher, Scientific Advisory Board

    Anesthesiologist & Pain Researcher, Scientific Advisory Board. NIH-funded, world-expert on T-type Calcium Channels & inhibitors in neuropathic pain. Professor of University of Virginia

  • Default avatar
    Slobodan Todorovic MD PhD
    Pain Researcher, Scientific Advisory Board

    Anesthesiologist & Pain Researcher, Scientific Advisory Board. NIH-funded, world-expert on T-type Calcium Channels & inhibitors in neuropathic pain. Professor of University of Virginia

  • Default avatar
    Lloyd Gray M.D.
    VP of Research

    Founder & VP of Tau Therapeutics. Formerly Professor of Pathology & Director of Clinical Immunology, UVA. Has over 34 peer-reviewed publications and 8 patents. MD University of Conn, Research Fellow at Sloan Kettering and Washington University.

  • Default avatar
    Michelle Higgin PhD
    Project Manager

    Chemistry & biochemistry, non-clinical drug development expertise. Former positions at Bayer, Magellan Laboratories, AAI and J&J.

  • Default avatar
    Timothy Macdonald PhD
    VP of Drug Discover

    Founder & VP of Tau Therapeutics, Prof of Chemistry & Pharmacology & immediate past Chairman of Chemistry, UVA. Over 280 publications and 40 patents. Founder of Adenosine Therapeutics LLC (sold to Clinical Data 2008) PhD Columbia University, NIH Fellow at Stanford. UVA Inventor of the Year--twice!

  • Default avatar
    Anne Heldreth J.D.
    Senior Analyst/Director of Operations & Compliance

    Cornell University Law School.

  • Default avatar
    Jim Barrow PhD
    Scientific Advisor

    T-type calcium channel expert, former Merck scientist now at Johns Hopkins who sits on Xdynia's Scientific Advisory Board

  • Default avatar
    Srinivasa Raja M.D.
    Scientific and Regulatory/FDA Advisor

    Pain Researcher, Johns Hopkins School of Medicine and sits FDA IMPACT Committee that evaluates all clinical pain trials

  • Default avatar
    Raymond Gilmartin
    Business Advisor

    former CEO Merck/Professor, Harvard Business School

  • Default avatar
    Christian Plaza J.D.
    General Counsel

    Cooley LLP: General Counsel

  • Default avatar
    Thomas Pajewski MD PhD
    Neuroanesthesiologist & Scientific Advisory Board

    Director of Department of Neuroanesthesiology, Professor, University of Virginia and practicing neuroanesthesiologist and former principal investigator

  • Default avatar
    George Golumbeski PhD
    Business Advisor

    SVP Business Development at Celgene and Business Advisor

  • Default avatar
    Dennis Turk PhD
    Scientific and Regulatory/FDA Advisor

    Pain Researcher, University of Washington School of Medicine & sits on FDA IMPACT Committee that evaluates all clinical pain trials and works on specific projects to improve sensitivity of clinical trials

Advisors

  • Default avatar
    Cooley LLP
    Lawyer
    Unconfirmed

Previous Investors

  • Default avatar
    Center for Innovative Technology, State of Virginia
    Unconfirmed
    Default avatar
    Multiple High-Net Worth Individuals
    Unconfirmed